Chemo-Immunotherapy: A New Trend in Cancer Treatment

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 10

PMID 37296876

Authors

Christian Sordo-Bahamonde

Seila Lorenzo-Herrero

Ana P Gonzalez-Rodriguez

Alejandra Martinez-Perez

Juan P Rodrigo

Juana M Garcia-Pedrero

Segundo Gonzalez

Affiliations

Soon will be listed here.

Abstract

Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate immune checkpoint inhibitor (ICI)-based therapy. Its effectiveness has been highlighted by recent regulatory approvals of various combinations of chemotherapy with ICIs in several tumors, particularly in some difficult-to-treat cancers. This review discusses the immune modulatory properties of chemotherapy and how they may be harnessed to develop novel chemo-immunotherapy combinations. It also highlights the key determinants of the success of chemo-immunotherapy and provides an overview of the combined chemo-immunotherapies that have been clinically approved.

Citing Articles

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.

Khorasanchi A, Hong F, Yang Y, Singer E, Wang P, Li M Cancer Drug Resist. 2025; 8:9.

PMID: 40051495 PMC: 11883235. DOI: 10.20517/cdr.2024.173.

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

PD-1/PD-L1 Inhibitors Increase Pathological Complete Response in Locally Advanced Gastric Cancer: A Meta-analysis and Trial Sequential Analysis.

de Moraes F, Sano V, Silva B, Silva A, Castro S, Kreuz M J Gastrointest Cancer. 2025; 56(1):49.

PMID: 39833372 DOI: 10.1007/s12029-024-01141-4.

Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.

Singh D, Haque S, Kim Y, Han I, Yadav D Front Immunol. 2024; 15:1455211.

PMID: 39720730 PMC: 11666570. DOI: 10.3389/fimmu.2024.1455211.

Role of immunotherapy in gastric cancer with liver metastasis.

Gafton B, Morarasu S, Dimofte G World J Clin Oncol. 2024; 15(11):1383-1389.

PMID: 39582613 PMC: 11514424. DOI: 10.5306/wjco.v15.i11.1383.

References

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Dong W, Wu X, Ma S, Wang Y, Nalin A, Zhu Z . The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discov. 2019; 9(10):1422-1437. PMC: 7253691. DOI: 10.1158/2159-8290.CD-18-1259. View

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M . Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 2013; 190(5):2464-71. PMC: 3578135. DOI: 10.4049/jimmunol.1202781. View

Alizadeh D, Trad M, Hanke N, Larmonier C, Janikashvili N, Bonnotte B . Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2013; 74(1):104-18. PMC: 3896092. DOI: 10.1158/0008-5472.CAN-13-1545. View

Li Y, Zhang H, Li Q, Zou P, Huang X, Wu C . CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett. 2020; 495:12-21. DOI: 10.1016/j.canlet.2020.09.011. View

Muliaditan T, Opzoomer J, Caron J, Okesola M, Kosti P, Lall S . Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clin Cancer Res. 2018; 24(7):1617-1628. PMC: 5889101. DOI: 10.1158/1078-0432.CCR-17-2587. View

Yamazaki T, Buque A, Ames T, Galluzzi L . PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020; 9(1):1721810. PMC: 7028345. DOI: 10.1080/2162402X.2020.1721810. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

10.

Eriksson E, Wenthe J, Irenaeus S, Loskog A, Ullenhag G . Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. J Transl Med. 2016; 14(1):282. PMC: 5041438. DOI: 10.1186/s12967-016-1037-z. View

11.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

12.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

13.

Kwon M, Jung H, Nam G, Kim I . The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. J Control Release. 2021; 331:321-334. DOI: 10.1016/j.jconrel.2021.01.009. View

14.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I . Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015; 4(4):e1008866. PMC: 4485780. DOI: 10.1080/2162402X.2015.1008866. View

15.

Hsu J, Hodgins J, Marathe M, Nicolai C, Bourgeois-Daigneault M, Trevino T . Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018; 128(10):4654-4668. PMC: 6159991. DOI: 10.1172/JCI99317. View

16.

Paz-Ares L, Ciuleanu T, Cobo M, Schenker M, Zurawski B, Menezes J . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):198-211. DOI: 10.1016/S1470-2045(20)30641-0. View

17.

Kaneno R, Shurin G, Tourkova I, Shurin M . Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med. 2009; 7:58. PMC: 2716306. DOI: 10.1186/1479-5876-7-58. View

18.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

19.

Voorwerk L, Slagter M, Horlings H, Sikorska K, Van de Vijver K, de Maaker M . Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019; 25(6):920-928. DOI: 10.1038/s41591-019-0432-4. View

20.

Topalian S, Taube J, Pardoll D . Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020; 367(6477). PMC: 7789854. DOI: 10.1126/science.aax0182. View